CatalYm joins Pfizer in pivotal cachexia push
Shortly after ponsegromab, visugromab is to start phase 2/3.
Novita goes into phase 3
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
Compass makes hay in bispecifics
Progress with three bispecific molecules is rewarded with a $120m equity raise.
IO comes agonisingly close to success
Keynote-D18 might have failed on a technicality, but now cash is running out.
